News
Mosaic gained ASTX029, an ERK1/2 inhibitor, and ASTX295, an MDM2 antagonist, in the deal, which it hopes to advance in biomarker-defined indications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback